



US009844545B2

(12) **United States Patent**  
**Tu et al.**

(10) **Patent No.:** **US 9,844,545 B2**

(45) **Date of Patent:** **\*Dec. 19, 2017**

(54) **METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET**

(2013.01); *A61K 9/2013* (2013.01); *A61K 9/28* (2013.01); *A61K 47/48176* (2013.01)

(71) Applicant: **Tris Pharma, Inc.**, Monmouth Junction, NJ (US)

(58) **Field of Classification Search**  
CPC ..... *A61K 9/20*; *A61K 9/2004*; *A61K 9/2072*; *A61K 9/2077*  
See application file for complete search history.

(72) Inventors: **Yu-Hsing Tu**, West Windsor, NJ (US); **Ashok Perumal**, Monmouth Junction, NJ (US); **Kalyan Kathala**, Monmouth Junction, NJ (US)

(56) **References Cited**

U.S. PATENT DOCUMENTS

(73) Assignee: **TRIS PHARMA, INC.**, Monmouth Junction, NJ (US)

2,990,332	A	6/1961	Keating et al.
3,138,525	A	6/1964	Koff
3,499,960	A	3/1970	MacEk
3,594,470	A	7/1971	Borodkin
3,979,349	A	9/1976	Fink
4,221,778	A	9/1980	Ragunathan
4,510,128	A	4/1985	Khanna
4,600,645	A	7/1986	Ghebre-Sallasi
4,762,709	A	8/1988	Sheumake
4,765,989	A	8/1988	Wong
4,794,001	A	12/1988	Mehta
4,871,549	A	10/1989	Veda
4,876,094	A	10/1989	Benton
4,891,549	A	1/1990	Geoghegan
4,894,239	A	1/1990	Nonomura et al.

(\* ) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(Continued)

(21) Appl. No.: **15/491,547**

(22) Filed: **Apr. 19, 2017**

(65) **Prior Publication Data**

US 2017/0216270 A1 Aug. 3, 2017

FOREIGN PATENT DOCUMENTS

**Related U.S. Application Data**

(63) Continuation of application No. 15/009,480, filed on Jan. 28, 2016, which is a continuation of application No. 14/872,226, filed on Oct. 1, 2015, now Pat. No. 9,295,642, which is a continuation of application No. 14/624,998, filed on Feb. 18, 2015, now Pat. No. 9,180,100, which is a continuation of application No. 14/300,580, filed on Jun. 10, 2015, now Pat. No. 8,999,386, which is a continuation of application No. PCT/US2013/054930, filed on Aug. 14, 2013, application No. 15/491,547, filed on Apr. 19, 2017, which is a continuation of application No. 15/009,468, filed on Jan. 28, 2016, which is a continuation of application No. 14/872,226, filed on Oct. 1, 2015, now Pat. No. 9,295,642, which is a continuation of application No. 14/624,998, filed on Feb. 18, 2015, now Pat. No. 9,180,100, which is a continuation of application No. 14/300,580, filed on Jun. 10, 2014, now Pat. No. 8,999,386, which is a continuation of application No. PCT/US2013/054930, filed on Aug. 14, 2013.

BE	729827	9/1969
CA	2742680 A1	5/2010
CA	2758556 A1	5/2013
CN	1179450	4/1998
DE	2246037	4/1974
EP	0294103	12/1988
EP	0367746	5/1990
EP	0565301	10/1993
EP	09434341	9/1999
EP	1186293	3/2002

(Continued)

(60) Provisional application No. 61/774,783, filed on Mar. 8, 2013, provisional application No. 61/683,513, filed on Aug. 15, 2012.

OTHER PUBLICATIONS

S. Borodkin et al., *Polycarboxylic Acid Ion-Exchange Resin Adsorbates for Taste Coverage in Chewable Tablets*, Journal of Pharmaceutical Sciences, 60(10): 1523-1527 (1971).

E. Cascade, et al., *Short-acting versus Long-acting Medications for the Treatment of ADHD*. Psychiatry (Edgemont); 5(8):24-27 (2008).

(Continued)

(51) **Int. Cl.**

<i>A61K 31/4458</i>	(2006.01)
<i>A61K 47/48</i>	(2006.01)
<i>A61K 9/00</i>	(2006.01)
<i>A61K 9/20</i>	(2006.01)
<i>A61K 9/24</i>	(2006.01)
<i>A61K 9/28</i>	(2006.01)

*Primary Examiner* — Micah Paul Young

(74) *Attorney, Agent, or Firm* — Howson & Howson LLP; Cathy A. Kodroff; Egon Berg

(52) **U.S. Cl.**

CPC ..... *A61K 31/4458* (2013.01); *A61K 9/0056* (2013.01); *A61K 9/20* (2013.01); *A61K 9/209*

(57) **ABSTRACT**

An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.

**30 Claims, 1 Drawing Sheet**